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Developmental Toxicology: Status ofthe
Field and Contribution of the National
Toxicology Program
by B. A. Schwetz and M. W. Harris'
The NTPhasconducteddevelopmentaltoxicity studieson morethan50chemicals, often inmultiplespecies. Several
chemicalscauseddevelopmentaltoxicityintheabsenceofanytoxicity tothemother. Althoughhazardtohumansisdeter-
mined bythelevelofexposuretothechemicalanditsinherenttoxicity, thoseagentsthatselectively disturbthe develop-
mentoftheconceptus areofparticular concern because othermanifestationsoftoxicity would not warn the motherof
overexposure. WhethertheL0AEL (lowest-observed adverseeffectlevel) formaternal toxicity washigh orlow did not
correlate withthepotential ofchemicalstocause developmentaltoxicity. Theformofdevelopmental toxicity that deter-
minedtheLOAELmostfrequentlywasdecreasedbodyweightinmiceandrts, butnotrabbits, wheretheLOAELwas
determined moreoften by anincrease inresorptions. Several in vitro andshort-term testsappearpromising as screens
topredicttheoWicomeofdevelopmentaltaicitystudiesinmama However,theonlyscreensthathaveundergoneformal
validationstudiesarethoseevaluated bytheNTP. Improvementsinourability topredictrisktohumanshavebeenlimited
by ourknowledgeofthemechanismsbywhichagentscausedevelopmental toxicity. Thus, futuregrowthisdependenton
a better understanding ofthe biological processes that regulate normal development, therein providing the necessary
frameworkforunderstanding mechanisms ofabnormaldevelopment.
Introduction
Althoughsubmammalian species wereusedformanydecades
toevaluate theeffectofenvironmental agents onthedevelopment
ofthe conceptus, the useofmammalian species dates back on-
ly toaroundthe turnofthelastcentury (1). Experimental mam-
malianteratology as wehaveknownitinthepastseveraldecades
came intobeing intheearly 1960s as aresultofthethalidomide
tragedy. The term "developmental toxicology" wasfirstbrought
intopublished writings byJames Wilson intheearly 1970s (2).
Developmental toxicologyhasevolvedduringthepastcoupleof
decades atthe interfacebetweenteratology andtoxicology. The
primary contributions ofteratologists weretheunderstanding of
the anatomy and the embryology of normal and abnormal
developmentandtheclinical importance thereof. Thecontribu-
tion ofthe toxicologist was the use ofinformation from animal
models and human studies to predict the potential ofagents to
adversely affect development of the unborn, predicting on a
populationbasis ratherthan anindividual basis. Theprimary in-
terestoftheteratologist wasthe causeofmajor malformations,
ratherthanthecomplete spectrumofalterations fromnormalthat
might result from exposure to some endogenous or exogenous
agent.
Thalidomide wasclearly aclassicalteratogeninhumans inthat
itcaused majormalformations, anddid so atlevels ofexposure
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that were not associated with other toxic effects to the mother.
Experienceintoxicologyandteratology laboratoriesduringthe
years afterthalidomide taughtus thatvery few chemicals were
classical teratogens inthesenseofthethalidomide experience.
Manyagents,however, causedotherformsofabnormaldevelop-
mentthatweremanifestas minormalformationsorvariations,
changes inembryonicandfetalgrowth, theoccurrenceofdeaths,
andfunctionalalterationsasaresultofexposureduringpregnan-
cy. We also learnedduring the firstcouple ofdecades ofinten-
sively testing chemicals that the typeofdefect observed in the
laboratory animals (rats, rabbits, mice, and hamsters) did not
alwayspredictthetypeofdefectthatmightbefound inhumans.
Asaresult, theabsenceofamajormalformationinalaboratory
animalstudydidnotassuretheabsenceofmajormalformations
in humans. Thus, the decision was made that animal testing
should notbe limited to finding "other thalidomides" because
any manifestation of developmental toxicity in animals may
predict sometype ofabnormality in humans. Theemphasis in
animal testing, therefore, switched from looking for classic
teratogens to looking for developmental toxicants, agents that
wouldcauseanincreaseintheoccurrenceofany oneofthefour
manifestations ofdevelopmental toxicity: death, structural ab-
normalities, altered growth, or functional deficits.
The first extensive description of the distinction between
teratology and developmental toxicology and its impact on
screening for agents that could potentially adversely affect
human development was contained in the Guidelinesfor the
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lishedby theEnvironmental ProtectionAgency in 1986(3). This
document thoroughly addressed state-of-the-art toxicity test
methods, provided an extensive reviewofa soundrationale for
interpreting the results ofdevelopmental toxicity studies, and
provided a useful perspective on the distinction between tera-
tology and developmental toxicology.
Thepurposeofthispaper istocommentontheevolving status
ofthe fieldofdevelopmentaltoxicology, tosummarizetheresults
ofthe developmental toxicology testing conducted by the Na-
tional Toxicology Program (NTP) anddiscuss generalizations
that can bedrawn fromthatbody ofknowledge, andtodescribe
what mustbedone for the field ofdevelopmental toxicology to
continue to evolve.
Maturity of Developmental Toxicology
Thereareanumberofcriteriaby whichtheevolutionary status
ormaturity ofany fieldoftoxicology canbejudged. Onemajor
criterion is whether there are agreed-upon test methods for
detecting theparticular type oftoxicity. In the caseofdevelop-
mental toxicology, wehavebeenusingessentially thesamepro-
tocol for about 25 years. Thousands of chemicals have been
evaluated using thisprotocol. Priortothalidomide(1961), there
were no official test guidelines for evaluating teratogenic or
developmentaltoxiceffectsofagentsthatmightbesubmittedto
aregulatory agency forapproval. Reproductivestudies werecon-
ducted that provided little confidence that an agent would not
cause developmental toxicity.
After the thalidomide tragedy, a series of workshops by
teratologists during 1964 and 1965 led to the establishment of
criteriaandprotocols fortestingagentsforteratogenicpotential.
These principles oftesting for teratogenic potential were cap-
tured inofficial guidelinesofthe Foodand Drug Administration
in 1966 (4). Theseguidelines, theproductofasmall numberof
insightful teratologists, have remained essentially unchanged
since 1966. Theemphasishasexpanded, asmentionedabove, to
screen fordevelopmentaltoxicity ratherthanjust, teratogenicity,
butthe protocol is essentially as it wasoriginally described. In
his review in 1985, Schardein (5) stated that reports of the
teratogenic potential ofmorethan2800chemicals werefound in
the literature. By thetimeofthiswriting, surely thenumberex-
ceeds 4000. Thus, there is considerable experience in many
laboratories worldwide using this standard protocol for evalu-
atingteratogenicity, andduringthepast 15 years, forevaluating
developmental toxicity. Theexperience inmeasuring for func-
tional deficitsis, ofcourse, much more limited. Thus, the field
ofdevelopmental toxicology is mature from the standpoint of
agreed-upon test methods, with lessexperience in measures of
functional deficits compared to other end points of develop-
mental toxicity.
Another measureofthematurityofthe fieldofdevelopmen-
tal toxicology is the identification ofknown human toxicants.
About 50drugsorchemicals havebeenassociatedinanecdotal
orcase reports oronthebasisofepidemiological datawith one
or more ofthe fourmanifestations ofdevelopmental toxicity in
humans (1). Thereareundoubtedly humandevelopmental tox-
icantsthathavenotbeenidentified. Clearly, thenumberofagents
identified asdevelopmental toxicants inlaboratoryanimals ex-
ceedsthosethathavebeenidentifiedassuchinhumans. Whether
this reflectsthehighdoselevelsusedinanimal studies foridenti-
fying developmental toxicity, whether animals are inherently
moresensitivetothesemanifestationsacrossbroadcategoriesof
chemicals, orwhetherthenumberofdevelopmental toxicants in
humans is seriously underestimated is notknown. Likely, each
ofthesefactorsistruetovaryingdegreesfordifferentagents. All
of the agents that are confirmed developmental toxicants in
humansarealsodevelopmentaltoxicants inlaboratoryanimals.
Thus, there is widely accepted evidence of adverse effects in
humans attributed to agents that also causedevelopmental tox-
icity in laboratory animals.
Maturityofafieldcanalsobemeasuredbytheamountofex-
periencewithrelevantanimalmodels. Asalreadymentioned, the
publishedliteraturecontainsreferencestoasmanyas4000agents
thathavebeenevaluated using ateratogenicity ordevelopmen-
taltoxicityprotocol. Thereisundoubtedly nootherstandardpro-
tocol for another end point oftoxicity using an in vivo animal
model (except, perhaps, foracute toxicity tests) where there is
moreexperience. However, ourdepthofunderstandingofthetest
model islimited. Thedevelopmentoftheembryoandfetusis so
complex that we do not have a lot ofdetailed knowledge about
normal development beyond morphological events that occur
during gestation. Therefore, developmental toxicity data have
beeninterpretedonanempiricalratherthanamechanisticbasis.
In the absence of thorough knowledge of the normal physio-
logicalprocesses, itisdifficulttounderstandwhataccountsfor
abnormal development following exposureto someagent. Cur-
rent efforts ofdevelopmental biologists to improve our under-
standing ofnormal development at the molecular level will be
extremely important to better understanding mechanisms of
abnormaldevelopment. Wehavereachedaplateauofunderstan-
ding ofour animal models that will likely not be exceeded by
simply testing more chemicals.
Another measureofmaturity is the level ofsophistication of
extrapolationofanimaldatatopredictthepossibility ofadverse
effects in humans. Developmental toxicity data are interpreted
on the basis that there is a threshold. Because of our lack of
understandingofmechanismsandtheassumptionthatthere is a
threshold for developmental toxicity (unless there is clear
evidence ofa genetic basis), regulators have predicted human
safety on the basis of calculated margins of human exposure
relative to dose levels in animal studies associated with the
absence ofan adverse effect. As a result, decisions about safe
levelsofexposuretodrugsorchemicalsrelativetodevelopmental
toxicpotentialarenotbasedonriskbutareinsteadbasedonsome
uncertainty factorthatisjudgedtobeadequateornotonanagent-
by-agent basis.
Thus, the maturity ofour approach for extrapolating from
animals tohumansmusttakeintoaccountseveralpointsofuncer-
tainty. First, theetiologyofthemajority ofdevelopmental tox-
icity observed in humans is unknown. We have to assume that
someunknownportionofthatdiseaseload isassociatedwith ex-
posure tochemicals acting as causative agentsby themselves or
in combination with other factors (nutrition, stress, etc.) or
chemicals. Second, in the absence ofchemical-specific mech-
anistic knowledge, we must assume that any adverse effect in
animalspredicts someeffect inhumans. Betterunderstanding of
ouranimal models and mechanisms ofabnormal development
will permit extrapolation between species with greater con-
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fidence and shouldpermitthe useofmore sophisticated models
for extrapolation that are mechanistically based.
Still another manifestation of the maturity of a field is its
knowledge ofmechanisms ofaction. Asalready mentioned, the
great complexity ofnormal development has precluded under-
standing themechanismsby which mosttoxicantsadversely af-
fect development. Critical steps in the development ofabnor-
malities areunderstood to someextentand in some casesthe pro-
ximate toxicant is known, but this is knowledge ofthe mode of
action ratherthan the ultimate mechanism ofaction.
In summary, the field ofdevelopmental toxicology is quite
mature in the sense of having standardized protocols for
evaluating toxicity, protocols thathavebeenusedforthousands
ofchemicals except for functional endpoints wherethere isless
experience. Thus, toxicologists and teratologists in many
laboratories worldwide have considerable experience with the
protocol, thebackground incidence ofabnormalities, and inter-
preting the results of such studies. However, our minimal
knowledge of the mechanism of action of teratogens and
developmental toxicants limits the level ofsophistication ofin-
terpretation and extrapolation ofdata from such studies.
Interpretation of Developmental
Toxicity Data
To assume thatafter25 years ofexperience using a standard-
ized protocol forevaluating developmental toxicity there would
be commonality within the field aboutthe interpretation ofthe
results ofsuch studies wouldbe amistake. Whilethereis consen-
sus on many issues, there are still disagreements aboutthe inter-
pretationofsome subtletiesofthedata. Thedisagreements stem
from several factors, including the amount of dependence on
statistical procedures, whether one is looking at the data for
evidenceofateratogenic response ordevelopmental toxicity, and
whether one is looking for a specific type ofeffect orall effects
consideredcollectively. Aworkshop washeld attheNational In-
stitute ofEnvironmental Health Sciences (NIEHS) inJune 1991
todiscuss the relative importance ofthevarious datacomponents
of a developmental toxicity study, both maternal and develop-
mental end points, how tointerpretchanges inthoseendpoints,
and how to integrate thedevelopmental andadulttoxicitydata to
reach a conclusion aboutpotential harm to humans. Participants
were selected on the basis ofexperience from within a broad
spectrum of backgrounds including clinical, basic research,
regulatory toxicology, statistics, etc. The majorcriteria that were
discussed include the ratio of the no-observed adverse effect
levels foradultanddevelopmental toxicity (theA/Dratio) poten-
cy, knowledge ofthe pattern or type ofeffect, the existence of
species concordance, andthe extent ofmechanistic knowledge.
The participants concluded that many criteria need to be con-
sidered when interpreting the results ofdevelopmental toxicity
studies andthat nosinglecriterion such astheA/Dratio orpoten-
cy was a sufficient basis for interpretation ofthe data. As with
many other manifestations oftoxicity, potential hazard tohumans
was considered to be a function ofhuman exposure to an agent
and its developmental toxicity, the latter reflecting the inherent
potential ofasubstance to cause an adverse effect onthedevelop-
ing conceptus under somedefined condition. All ofthecriteria
discussed intheworkshop wereconsidered tobeofimportance
incharacterizing developmental toxicity, the relative importance
ofindividualcriteriabeing afunctionofthequestionunder con-
sideration (6). Future progress in understanding mechanisms of
developmental toxicity will likely help to refine the process of
identifying potential hazards to humans.
Summary of NTP Developmental
Toxicity Studies
This sectionisintendedtoprovide athorough reviewofNTP
developmental toxicity studies conducted atthe NIEHS. In ad-
dition toproviding abriefsummaryofallofthestudies, several
generalizations regardingthecompletedatabasewill bediscuss-
ed. Particularly, thefollowingquestions willbeaddressedrelated
tochemicals: Forwhichchemicals wasdevelopmental toxicity
observed intheabsenceofmaternal toxicity? Whatchemicalsaf-
fected multiple end points (death, malformations, variations,
growthretardation)? Wasthere any segregationofdevelopmental
toxicity according to the LOAEL for maternal toxicity? Other
questions willbeaddressedrelated totheanimal modelsand in-
terspecies comparisons: What developmental toxicity was
observed atthe LOAEL? What additional developmental toxic
effects were observed above the LOAEL? What is the in-
terspecies predictiveness?
TheNTPdatabaseconsistsof85 studies on50chemicals: 32
in rats, 39 inmice, 13 inrabits, and 1 inhamsters. Exceptforsix
ofthe chemicals that were tested within the NIEHS facility, all
other studies wereconducted in two laboratories outside ofthe
NIEHS. The inhalation studies (except for the arsine studies)
wereconducted atBattellePacific NorthwestLaboratories, Rich-
land, Washington, under an interagency agreement with the
NTP. The noninhalation studies (except those done at NIEHS)
wereconductedinthelaboratories ofthe ResearchTriangle In-
stitute, ResearchTrianglePark, NorthCarolina. All chemicals
were tested between the years of 1980 and 1991 in American
AssociationforLaboratory Animal Care-certifiedlaboratories
underGoodLaboratory Practices conditions. Theprotocol for
conducting the studies and interpreting the presence ofaltera-
tions from normal was uniform among the three laboratories,
although individual studies weretailored to specificquestions on
individual chemicals. Withinthethreelaboratories, the samekey
personnel were involved in the studiesthroughout the entire ex-
perimental period.
Table 1. NTPstudies by route/mode ofexposure.
No. ofchemicals No. ofstudies
Gavage
Corn oil 11 17
Distilled water 20 34
Feed 9 12
Inhalation 9 16
Drinking water 1 I
Intravenous 2 3
Intraperitoneal 1 1
Subcutaneous 1 1
Total 54; 85
aTwo chemicals by two routes each.
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Table 2. Summary ofNTP
Chemical
Acetone
Acetone
Acrylamide
Acrylamide
Arsine
Arsine
Bendectin
Bisphenol A
Bisphenol A
Boric acid
Boric acid
Boric acid
1,3-Butadiene
1,3-Butadiene
Butyl benzyl phthalate
Butyl benzyl phthlate
Carbondisulfide
Carbon disulfide
Chloroprene
Chlorpromazine HCI
Chlorpromazine HCI
Codeine
Codeine
2',3'-Dideoxycytidine
Diethylene glycol
Diethylene glycol diethyl ether
Diethylene glycol diethyl ether
Diethylene glycol dimethyl ether
Diethylene glycol dimethyl ether
Diethylhexyl phthalate
Diethylhexyl phthalate
Diethyl phthalate
Dimethyl phthalate
Diphenhydramine
Diphenhydramine
Diphenhydramine
Dipropylene glycol
Ethylenechlorohydrin
Ethylene chlorohydrin
Ethylene chlorohydrin
Ethylene chlorohydrin
Ethylene chlorohydrin
Ethylene glycol
Ethylene glycol
Ethylene glycol
Ethylene glycoldiethyl ether
Ethylene glycoldiethyl ether
Ethylene glycol monobutyl ether
Ethylene glycol monobutyl ether
Ethylene oxide
Ethylene oxide
2-Ethylhexanol
Gallium arsenide
Gallium arsenide
Gentian violet
Gentian violet
1,2,3,4,7,8-Hexachlorodibenzofuran
n-Hexane
n-Hexane
Hydrochlorothiazide
Hydrochlorothiazide
1,5-Hydroxytryptophan
1,5-Hydroxytryptophan
Isoprene
Isoprene
Isoproterenol HCI
Isoproterenol HCI
Methyacrylamide
CAS no.
67-64-1
67-64-1
79-06-1
79-061
7784-42-1
7784-42-1
8064-77-5
80-05-7
80-05-7
10043-35-3
10043-35-3
10043-35-3
106-99-0
106-99-0
85-68-7
85-68-7
75-15-0
75-15-0
107-05-1
50-53-3
50-53-3
76-57-3
76-57-3
7481-89-2
111-46-6
112-36-7
112-36-7
111-96-6
111-96-6
117-81-7
117-81-7
84-66-2
131-11-3
147-24-0
147-24-0
147-24-0
25265-71-8
107-07-3
107-07-3
107-07-3
107-07-3
107-07-3
107-21-1
107-21-1
107-21-1
629-14-1
629-14-1
111-76-2
111-76-2
75-21-8
75-21-8
104-76-7
1303-00-0
1303-00-0
548-62-9
548-62-9
110-54-3
110-54-3
58-93-5
58-93-5
56-69-9
56-69-9
78-79-5
78-79-5
51-30-9
51-30-9
79-39-0
NTIS no.
DE89005671
DE89005671
PB89164669/AS
PB89140008/AS
PB84193879
PB85205110/AS
PB85205102/AS
PB91137588/AS
PB91132332
PNL-6414
PNL-6412
PB90115346/AS
PB91129999
PB84192343
PB84192350
PB83191080
PB83179846
PB87209524/AS
PB88131040/AS
PB91159327
PB88168257/AS
PB88168497/AS
PB86135233/AS
PB87209532/AS
PB85105658
PB85105674
PB89140081/AS
PB89164826/AS
PB83180612
PB83148684
PB83163055
PB85104594/GAR
PB85105385/GAR
PB91211219
PB88134093
PB88157516/AS
PB89165849/AS
PB89165849/AS
PB83242016
PB83242016
PB91185900
PNL-7367
PNL-7367
PB85103588/GAR
PB85103570/GAR
PB83231332
PB83231670
PNL-6829
PNL-6829
PB83153007
PB91208678
Species
Rat
Mouse
Rat
Mouse
Rat
Mouse
Rat
Rat
Mouse
Rat
Mouse
Rabbit
Rat
Mouse
Rat
Mouse
Rat
Rabbit
Rabbit
Rat
Mouse
Mouse
Hamster
Mouse
Mouse
Mouse
Rabbit
Mouse
Rabbit
Rat
Mouse
Rat
Rat
Rat
Mouse
Mouse
Rat
Mouse
Mouse
Mouse
Mouse
Rabbit
Rat
Mouse
Rabbit
Mouse
Rabbit
Rat
Rat
Rabbit
Rabbit
Mouse
Rat
Mouse
Rat
Rabbit
Mouse
Rat
Mouse
Rat
Mouse
Rat
Mouse
Rat
Mouse
Rat
Rat
Mouse
Route
Inhalation
Inhalation
po/gavage
po/gavage
bihalation
Inhalation
po/gavage
po/gavage
po/gavage
po
po
po/gavage
Inhalation
Inhalation
po
po
po/gavage
po/gavage
Inhalation
po/gavage
po/gavage
po/gavage
po/gavage
po/gavage
po/gavage
po/gavage
po/gavage
po/gavage
po/gavage
po
po
po
po
po/gavage
po/gavage
po/gavage
po/gavage
iv
iv
iv
iv
iv
po/gavage
po/gavage
po/gavage
po/gavage
po/gavage
po/gavage
po/gavage
iv
iV
pO
Inhalation
Inhalation
po/gavage
po/gavage
po/gavage
Inhalation
Inhalation
po/gavage
po/gavage
po/gavage
po/gavage
Inhalation
Inhalation
ip
sc
po/gavage
Vehicle
Air
Air
Water
Water
Air
Air
Water
Cornoil
Cornoil
Feed
Feed
Water
Air
Air
Feed
Feed
Corn oil
Cornoil
Air
Water
Water
Water
Water
Water
Water
Water
Water
Water
Water
Feed
Feed
Feed
Feed
Water
Water
Water
Water
Water
Water
Water
Water
5% dextrose
water
Water
Water
Water
Water
Water
Water
5% dextrose
5% dextrose
Feed
Air
Air
Water
Water
Corn oil
Air
Air
Corn oil
Corn oil
Corn oil
Corn oil
Air
Air
Saline
Saline
Water
Treatment
g/day
6-19, 6 hr/day
6-17, 6 hr/day
6-20
6-17
6-15, 6 hr/day
6-15, 6 hr/day
6-15
6-15
6-15
0-20
0-17
6-19
6-15, 6 hr/day
6-15, 6hr/day
6-15
6-15
6-15
6-19
6-28, 6 hr/day
6-15
6-15
6-15
5-13
6-15
6-15
6-15
6-19
6-15
6-19
0-20
0-17
6-15
6-15
6-15
11-14
6-15
6-15
4-6
6-8
8-10
10-12
6-14
6-15
6-15
6-19
6-15
6-19
9-11
11-13
6-9
6-14
0-17
4-19
4-17
6-15
6-19
10-13
6-19
6-17
6-15
6-15
6-15
6-15
6-19
6-17
6-15
6-15
6-17
Dose range
440 11000 ppm
440-6600 ppm
2.5-15 mg/kg
3-45 mg/kg
0.025-2.5 ppm
0.025-2.5 ppm
200-800 mg/kg
160-1280 mg/kg
500-1250 mg/kg
0.1-0.4%
0.1-0.4%
62.5-250 mg/kg
40-1000 ppm
40-1000 ppm
0.5-2.0%
0.1-1.25%
100-600mg/kg
25-150 mg/kg
10-175 ppm
5-45 mg/kg
2.5-30 mg/kg
37.5-450 mg/kg bid
10-150 mg/kg bid
200-2000 mg/kg
1250-10000 mg/kg
300-4500mg/kg
50-400mg/kg
62.5-500 mg/kg
25-175 mg/kg
0.5-2.0%
0.25-0.15%
0.25-5.0%
0.25-5.0%
25-100 mg/kg
80-200mg/kg
40-160mg/kg
800-5000 mg/kg
60-120 mg/kg
60-120mg/kg
60-120 mg/kg
60-120 mg/kg
9-36 mg/kg
1250-5000 mg/kg
750-3000mg/kg
100-2000mg/kg
50-1000 mg/kg
25-100 mg/kg
30-200 mg/kg
30-300 mg/kg
18-36 mg/kg
9-36 mg/kg
0.009-0.09%
10-75 mg/cu m
10-75 mg/cu m
2.5-10mg/kg
0.5-2.0 mg/kg
0.1- I mg/kg
200-5000 ppm
200-5000ppm
100-1000mg/kg
300-3000 mg/kg
50-300 mg/kg
50-450mg/kg
280-7000 ppm
280-7000 ppm
20-80mg/kg
0.25-20mg/kg
60-180mg/kg
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developmental toxicity studies.
NOAEL LOAEL
A/D A
1 11000
1 6600
<0.2 7.5
0.2 15
.0.2 2.5
<0.2 2.5
1 500
<0.03 <160
<0.5 <500
>1 0.2
2 0.4
1 250
<0.2 1000
>1 200
1 1.25
1 1.25
1 200
>1 75
- >175
- .5
0.5 5
1 150
5 150
2.5 2000
0.25 5000
0.2 1500
<0.5 400
2 250
1 100
1 1
2 0.1
1 5
.0.2 5
0.5 50
- .80
0.5 80
0.4 2000
1 120
1 120
>1 120
1 120
<0.25 18
- . 1250
>1 1500
.0.5 2000
3.3 1000
2 100
0.3 100
<0.1 100
- >36
0.5 18
- >0.09
1 37
<1 .10
0.5 5
- .0.5
>6 1
1 1000
.5 >5000
0.3 1000
- >3000
1 300
s1 <50
- >7000
>5 7000
- 20
- .0.25
1 120
LOAEL
D
11000
6600
>15
45
>2.5
>2.5
500
1250
<0.1
0.2
250
> 1000
.40
1.25
1.25
200
.25
>175
25
15
150
50
1000
10000
3000
>400
125
100
1
0.05
5
>5.0
100
.80
160
5000
120
120
<60
120
>36
. 1250
.750
>2000
500
50
200
>300
>36
36
>0.09
37
37
10
<0.5
1000
5000
>1000
>3000
300
150
>7000
.280
.20
.0.25
120
LOAEL Developmental Developmental
A/D toxicity at LOAEL toxicity above LOAEL Reference
1 bw No higher level
1 bw, death, var No higher level
<0.5 None None (14)
0.3 bw Nohigher level (14)
<1 None None (15)
<1 None None (15)
1 bw bw, death, mal (16)
- None None (17)
<0.4 bw, death No higher level (17)
>2 bw bw, death, mal (18)
2 bw bw, death, mal, var (18)
1 Death, mal No higher level (19)
<1 None None (20)
25 bw bw, var (20)
1 Mal, var Death, bw, mal, var
1 bw, death, mal, var No higher level
1 bw bw
3r > Death Death, mal
- None None
- bw bw, death
0.3 bw bw, death, mal
1 bw bw, death (21)
3 bw bw, death, mal (21)
2 bw, mal bw, death, mal (22)
0.5 bw No higher level
0.5 bw No higher level
<1 bw No higher level
2 bw bw, death, mal, var (23)
1 Death, mal, var Death, mal, var
1 bw bw, death (24)
2 mal, var bw, death, mal, var (24)
1 Var No higherlevel
<1 None None
0.5 bw No higher level
- bw bw
0.5 bw, death No higher level
0.4 bw Nohigher level
1 bw, death No higher level
1 bw No higher level
- bw bw
1 bw Nohigher level
<0.5 None None
- Mal, var bw, death, mal, var (25)
2or > bw bw, death, mal, var (25)
<1 None None
2 Mal bw, death, mal, var (26)
2 Mal Death, mal, var (26)
0.5 Death Nohigher level
<0.3 None None
- None None
0.5 Death Nohigherlevel
- None None
1 bw,var bw
<0.3 bw, var bw, death
0.5 mal nohigher level
- bw bw
- bw, mal bw, mal (27)
1 bw bw
>I bw, death Nohigher level
< I None None
- None None
I Mal Nohigher level
<0.3 Var bw, var
- None None
.25 bw bw, var
- bw bw
- bw bw, death
I bw bw, death
continued
NOAEL
A
2200
2200
2.5
3
0.5
0.5
200
< 160
<500
0.1
0.2
125
200
40
0.5
0.5
100
25
175
<5
2.5
75
50
1000
1250
300
200
125
50
0.5
0.05
2.5
I
25
<80
40
800
60
60
60
60
9
<1250
750
1000
500
50
30
30
36
9
0.09or
10
<10
2.5
<0.5
0.6
200
5000
300
3000
150
50
7000
1400
<20
<0.25
60
NOAEL
D
2200
2200
>15
15
>2.5
>2.5
200
>640
1000
<0.1
0.1
125
I1000
<40
0.5
0.5
100
<25
> 175
<5
S
75
10
400
5000
1500
>400
62.5
50
0.5
0.025
2.5
>5.0
50
<80
80
2000
60
60
<60
60
>36
<1250
<750
>2000
150
25
100
>300
>36
18
0.09
10
10
S
<0.5
<0.1
200
1000
> 1000
3000
150
50
7000
<280
<20
<0.25
60
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Table2. Summary ofNTP
Treatment
Chemical CAS no. NTIS no. Species Route Vehicle g/day Dose range
a-Methyldopa 41372-08-1 PB86245321/AS Rat po/gavage Cornoil 6-20 50-500 mg/kg
a-Methyldopa 41372-08-1 PB87172607/AS Mouse po/gavage Corn oil 6-17 100-750 mg/kg
Methyl ethyl ketone 78-93-3 PNL-6833 Mouse Inhalation Air 6-15 400-3000 ppm
Mono(2-ethylhexyl)phthalate 4376-20-9 PB91185926 Mouse po Feed 0-17 0.017-0.140%
Nitrofurazone 59-87-0 PB86145844/AS Mouse po Feed 6-15 0.0038-0.05%
Nitrofurazone 59-87-0 PB88130984/AS Rabbit po/gavage Corn oil 6-19 5-20 mg/kg
Oxytetracycline 2058-46-0 PB83182469 Rat po/gavage Corn oil 6-15 1200-1500 mg/kg
Oxytetracycline 2058-46-0 PB83151027 Mouse po/gavage Corn oil 6-15 1325-2100 mg/kg
1,2,3,7,8-Pentachlorodibenzofuran Mouse po/gavage Cornoil 10-13 0.001-0.2 mg/kg
2,3,4,7,8-Pentachlorodibenzofuran Mouse po/gavage Cornoil 10-13 0.001-0.08 mg/kg
Perfluorodecanoic acid Mouse po/gavage Corn oil 6-15 0.03-12.8 mg/kg
Phenol 108-95-2 PB83247726 Rat po/gavage Water 6-15 30-120 mg/kg
Phenol 108-95-2 PB85104461 Mouse po/gavage Water 6-15 70-280 mg/kg
Scopolamine HBr 114-49-8 PB87235412/AS Rat po/gavage Water 6-15 10-900mg/kg
Scopolamine HBr 114-49-S PB87209516/AS Mouse po/gavage Water 6-15 10-900mg/kg
Sulfamethazine 57-68-1 PB83151035 Rat po/gavage Water 6-15 545-865 mg/kg
Sulfamethazine 57-68-1 PB85172047/AS Rabbit po/gavage Water 6-19 600-1800mg/kg
Tetrahydrofuran 109-99-9 DE89001383/LL Rat Inhalation Air 6-19 600-5000 ppm
Tetrahydrofuran 109-99-9 DE89001383/LL Mouse Inhalation Air 6-17 600-5000 ppm
Theophylline 58-55-9 PB86108172 Rat po Feed 6-15 0.15-0.40%
Theophylline 58-55-9 PB86103223 Mouse po Drink, water 6-15 0.075-0.20%
Triethylene glycol dimethyl ether 112-49-2 PB86103215 Mouse po/gavage Water 6-15 250-1000 mg/kg
Triethylene glycol dimethylether 112-49-2 PB87181657/AS Rabbit po/gavage Water 6-19 75-250mg/kg
Abbreviations: po, peros; bw, body weight; var, variations; mal, malformations; NOAEL, no-observed adverseeffectlevel; LOAEL, lowestobserved adverse
Itmustbemadeclearthatthe50chemicals werenotselected
ona randombasisand are, therefore, notrepresentativeofthe
universe ofchemicals. Chemicals were selected fortesting on
the basis ofhuman exposure, preexisting data suggesting that
thesemaybedevelopmentally toxicinsinglespeciesorinin vivo
orshort-termscreeningdata, structure-activity considerations,
or a specific request for a developmental toxicity study by a
governmentagency. Therefore, anygeneralizationsdrawnfrom
the resultsofstudies onthese50chemicalsmay notapply more
generally.
The route and mode ofexposure ofthese 85 studies is sum-
marized in Table 1. Compared to theuniverse ofchemicals, a
disproportionatelyhighproportionofthechemicalstestedinthe
NTP studies were watersoluble and were given in an aqueous
vehicle.
The accounting ofstudies conducted through the NIEHS is
summarized in Table 2. The NTIS number is provided for
anyone whowants toobtain acopyofthestudy reportfromthe
National Technical Information Services.* Studies that were
conducted in-house at NIEHS do nothave an NTIS number as
their study reportconsisted ofapublishedmanuscriptwhichis
cited. Both the NOAEL(no-observed adverseeffectlevel) for
adult and developmental toxicity are provided along with the
LOAEL (lowest-observed adverse effect level) for adult and
developmental toxicity toemphasize theimportanceofthedose
selection on the determination ofthese two numbers. In those
studies wheredevelopmental toxicity wasobservedatsomedose
level, theeffectthatdetermined the LOAEL isidentifiedalong
with any additional toxicities that were observed above the
LOAEL. Alloftherawdatafromthesestudies resideintheNTP
Archive in Research Triangle Park, North Carolina.
*U.S. Department ofCommerce, NTIS, Springfield, VA 22161; (703) 487-4600.
Severalspecial studiesarenotincludedinTable2becauseof
thedesignorpurposeofthestudies. Includedamongthose not
listed, for example, is a study on 1,1,l-trichloroethane to
evaluatetherepeatabilityofacardiacmalformationreportedin
thepublishedliterature. Thisstudy did notinclude acomplete
evaluation of other possible alterations beyond the car-
diovascularsystem(7). Acomparisonofthecontroldatausing
distilled waterversuscomoilasvehicleshasbeenreported(8).
The initial comparison ofthese two vehicles suggested some
statistically significant differences. A subsequent study con-
ducted at one time using large numbers of animals failed to
repeattheobservationthatwassuggestedbasedonacollection
ofcontrol groups from individual studies (9).
ThecriteriabywhichtheNTPinterpretedtheresultsofthese
studies areconsistentwiththose identifiedearlierastheconclu-
sionsoftheNTPworkshopheldtoreviewthecriteriaforinter-
pretingdevelopmental toxicity studies. Amajorconsideration
was the presence ofdevelopmental toxicity in thepresence or
absenceofmaternaltoxicity. Theresultsofeachstudyhavebeen
analyzed onthebasis ofstatistically ortoxicologically signifi-
cant increases intheoccurrence offetal deaths orresorptions,
changes in fetalbody weight atthe timeofCaesarean section,
or significant increases in the incidence ofmalformations or
variations. Thepresenceofchangesintheseendpoints was con-
sidered relative tothepresenceofmaternaltoxicity. Thus, each
studyhasbeenclassifiedintooneoffourcategories onthebasis
ofthe outcome summarized in Table 3: developmental toxici-
tyobservedintheabsenceofadulttoxicity,developmental tox-
icityobserved inthepresenceofadulttoxicity, nodevelopmen-
taltoxicity observedinthepresenceofsignificantadulttoxici-
ty, orthestudyis notclassifiable onthebasisofthenatureofthe
developmentaloradulttoxicity. Anexampleofanunclassifiable
outcomewouldbeastudy whereadulttoxicity wasobserved at
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developmental toxicity studies (continued).
NOAEL NOAEL NOAEL LOAEL LOAEL LOAEL Developmental Developmental
A D A/D A D A/D toxicity at LOAEL toxicity above LOAEL Reference
50 50 1 100 100 I bw bw
100 250 0.4 250 500 0.5 bw, death, mal, var bw, death, mal, var
3000 1000 23 >3000 3000 >I bw Nohigherlevel (28)
0.017 0.017 1 0.035 0.035 1 Death, mal bw, death, mal
0.025 0.025 1 0.05 0.05 1 bw No higher level
15 15 1 20 20 1 Death, mal No higher level
< 1200 < 1200 - 1200 1200or < - bw bw (29)
< 1325 2100or > <1 < 1325 >2100 <1 None None (29)
0.03 0.01 3 0.1 0.03 3.3 Mal Mal (27)
0.01 0.003 3.3 0.02 0.01 2 Mal Mal (27)
3 0.3 10 6.4 1 6.4 bw bw (30)
> 120 60 >2 - 120 - bw Nohigher level
140 140 1 280 280 1 bw bw
10 10 1 100 100 I bw Death, mal
100 100 1 450 450 1 bw bw
685 545 1.2 865 685 1.3 Mal bw, mal
600 1500 0.4 1200 1800 0.7 Death Nohigher level
1800 1800 1 5000 5000 1 bw Nohigher level
600 1800 0.3 1800 5000 0.4 Death Nohigher level
0.3 0.15 2 0.4 0.3 1.3 bw bw (31)
0.075 0.075 1 0.15 0.15 1 bw, death bw, death (31)
1000or > 250 4or > > 1000 500 >2 bw bw, mal (32)
125 125 1 175 175 1 Var Mal,var
effect level; A, adult; D, developmental.
all dose levels so that NOAELs werenotdetermined.
The specific protocols used for the developmental toxicity
studies varied somewhat from study to study and between
laboratories, butthebasicprotocol wasdesigned tohaveatleast
three treated groups and one control group and at least 20
pregnancies, regardless of species, in each group. Pregnant
females werekilled 1 daybeforetheexpecteddeliverydatefor
eachspecies, andthenumberofcorporalutea, implants, liveand
dead fetuses, resorptions, and fetal bodyweight wererecorded
at the time ofCaesarean section. External malformations and
variations were recordedbased onexaminations atthetimeof
Caesarean section. Fetalsexwasdeterminedonthebasisofex-
ternal or internal genitalia. Examination forvisceralmalforma-
tions was conductedaccording tothemethodofStaples(10). All
fetuses ofeach litter wereexamined forvisceral malformations
and variations andweresubsequently cleared andstainedforex-
amination for skeletal alterations. All studies conducted at
Research Triangle Institute weredoneusing areplicatedesign.
Data were analyzed for the presence ofpairwise differences
from control as well as the presence oftrends.
Those chemicals that caused developmental toxicity in the
absenceofany significantmaternaltoxicity aresummarized in
Table4. Thenumberofspeciestestedforeachchemical varied.
The number of species in which developmental toxicity was
observed intheabsenceofmaternal toxicity isindicatedbythe
column heading. Forexample, studieswereconductedonboric
acid inthreespecies, twoofwhichshoweddevelopmental tox-
icity in theabsenceofmaternal toxicity. Regardingthepossibili-
ty that exposure ofhumans to these or other chemicals might
representapotential risk, itis importanttoreiterate thatpoten-
tial risk is a function ofboth exposure and the ability of the
chemical to produce developmental toxicity. Among those
chemicals that have some propensity to cause developmental
toxicity, itseemslogicalthatchemicalssuchasthalidomidethat
tend to cause developmental toxicity in the absence of any
adverseeffectonthemotherrepresentsomewhatmoreofacon-
cernthanagentsthataredevelopmentallytoxiconlyatlevelsof
maternalexposurethatcauseothermanifestationsoftoxicity ex-
ceptinthosecaseswherehumansareexposedatdoselevelstox-
ic to the adult.
Another consideration regarding the nature ofthe develop-
mentaltoxiceffectscausedbydifferentchemicalsistheprofile
oftoxiceffectsobserved. Disregarding thedoselevel atwhich
effects mightbeobserved, it seems intuitively important to be
moreconcernedaboutagentsthatcauseasignificantincreasein
avariety ofalterations as opposed to achange inonly one end
point because ofthe multiplicity ofend points involved with
multiple effects and the increased probability that some
mechanismwouldbeoperativeinhumans. Thosechemicalsthat
causesignificant increases indeath, growhretardation, malfor-
mations, andvariations aresummarizedinTable5. Interesting-
ly, fiveofthesevenchemicalsonthislistarealsoamongthose
that caused developmental toxicity in the absenceofmaternal
toxicity (Table 4).
AreviewoftheLOAELsformaternaltoxicitylistedinTable
6revealsawiderangeofnumbersforthe50chemicals. This is
trueforinhalationandotherroutesofexposure. Inaddition, for
someofthechemicalsthatweretestedinmultiplespecies, there
were significantspeciesdifferences inthematernal LOAELs.
Forexample, inthecaseofacetonebytheinhalation route, the
maternalLOAELsdifferedroughlybyafactoroftwoformouse
and rat. In the case of boric acid, the difference was much
greater, withmicebeingmuchmoretolerantthanratsofrabbits.
There was a5-folddifference inmaternal LOAELfor inhaled
1,3-butadiene. Asimilarbutreverseddifferenceexistedforin-
haledn-hexane, withmicebeingmuchmoretolerantthanrats.
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Table 3. Developmental toxicity studies: outcome by species.
Outcome at the LOAEL by speciesa
Chemical Mouse Rat Rabbit Hamster
Acetone +/+ +/+
Acrylanlide -/+ -/+
Arsine -/+ -/+
Bendectin +/+
Bisphenol A -/+
Boric acid +/- +/- +/+
1,3-Butadiene +/- -/+
Butyl benzyl phthalate +/+ +/+
Carbon disulfide +/+ +/-
Chloroprene NC
Chlorpromazine HCI -/+ NC
Codeine +/+ +/-
2',3-Dideoxycytidine
Diethylene glycol -/+
Diethylene glycol diethyl ether -/+ -/+
Diethylene glycol dimethyl ether +/- +/+
Diethylhexyl phthalate +/- +/+
Diethyl phthalate +/+
Dimethyl phthalate -/+
Diphenhydramine -/+ (gd 6-15) -/+
Dipropylene glycol
Ethylene chlorohydrin +/+ (gd 4-6)
Ethylene chlorohydrin +/+ (gd 6-8)
Ethylene chlorohydrin +/- (gd 8-10)
Ethylene chlorohydrin +/+ (gd 10-12)
Ethylene glycol +/- NC -/+
Ethylene glycol diethyl ether +/-
Ethylene glycol monobutyl ether -/+ (gd 9-11) +/-
Ethylene glycol monobutyl ether -/+ (gd 11-13)
Ethylene oxide NC (gd 6-9)
Ethylene oxide -/+ (gd 6-14)
2-Ethylhexanol NC
Gallium arsenide +/+
Gentian violet -/+ NC
1,2,3,4.7.8-Hexachlorodibenzofuran +/-
,i-Hexane +/- +/+
Hydrochlorothiazide NC -/+
L,5-Hydroxytryptophan -/+ +/+ Isoprene +/- NC
Isoproterenol HCI NC (IP) Isoproterenol HCI NC (SC)
Methacrylamide +/+
a-Methyldopa -+/+
Methyl ethyl ketone
Mono(2-ethylhexyl)phthalate +/+
Nitrofurazone +/+ +/+
Oxytetracycline -/+ NC
1,2,3,7,8-Pentachlorodibenzofuran +/-
2,3,4,7,8-Pentachlorodibenzofuran -
Perfluorodecanoic acid +/-
Phenol +/+ +1-
Scopolamine HBr +/+ +/+
Sulfamethazine +/- -/+
Tetrahydrofuran -/+ +/+
Theophylline +/+ +/-
Triethylene glycol dimethyl ether +/- +/+
Abbreviations: NC, not classifiable, gd, gestation day; LOAEL, lowest-observed adverse effect level.
"Outcome code is reported as positive or negative developmental toxicity/positive or negative maternal toxicity.
With this wide range in the maternal LOAELs, which deter- studies according to the maternal LOAEL. Chemicals are
mines the highest dose level in the experimental toxicity segre- grouped according to those with a LOAEL for maternal toxici-
gated according tothe range ofmaternal LOAEL. Inotherwords, ty of less than 50 mg/kg, or LOAELs in the range of 50-500
was there a predilection fordevelopmental toxicity based on the mg/kg, 500-1000, or greater than 1000 mg/kg. Table 8 sum-
potency for maternal toxicity? The information presented in marizes an analysis of these data. Chemicals that caused
Table 7 summarizes the outcome ofthe developmental toxicity developmental toxicity in the absence of maternal toxicity or
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Table 4. Chemicals with developmental toxicity in the absence of
maternal toxicity.
Two species One species
Boric acid X (3)a
1,3-Butadiene X (2)
Carbon disulfide X (2)
Codeine X (2)
2.3-Dideoxycytidine X (1)
Diethylene glycol dimethyl ether X (2)
Diethylhexyl phthalate X (2)
Ethylene chlorohydrin X (2)
Ethylene glycol X (3)
Ethylene glycol diethyl ether X (2)
1,2,3.4.7,8-Hexachlorodibenzofuran X (1)
n-Hexane X (2)
Isoprene X (2)
Methyl ethyl ketone X (1)
1,2,3,7,8-Pentachlorodibenzofuran X (1)
2,3,4,7,8-Pentachlorodibenzofuran X (1)
Perfluorodecanoic acid X (1)
Phenol X (2)
Sulfamethazine X (2)
Theophylline X (2)
Triethylene glycol dimethyl ether X (2)
aTotal number ofspecies studied in parentheses.
those agents that were clearly not developmentally toxic (no
developmental toxicity in the presence ofsignificant maternal
toxicity) weredistributed across thevariouscategories ofmater-
nal LOAEL. Thus, selective effects on the developing concep-
tusdid not segregateaccording tomaternal LOAEL, suggesting
alackofassociation ofdevelopmental toxicitypotential andthat
forother measuresofmaternal toxicityusedto selectdoselevels.
In additionto the abovediscussion that focusedprimarily on
chemical-specific developmental toxicity, severalpoints warrant
discussion regarding theanimal model used forthese studies and
comparisons between species. Because ofknown species dif-
ferences intheprofileofspontaneousand inducedalterations in
developmentandbecauseofthedifference inthelengthoftime
between thelastday ofchemical administration andthetimeof
Caesarean section, onewould expecttofindspeciesdifferences
Table5. Cheniicalsaffectingmultipleendpointsofdevelopmentaltoxicity.
Outcome
Chemical Species categorya Comment
Boric acid Mouse +/-
Butyl benzyl phthalate Rat +/+ Developmental toxicity at
dose level where most
litterstotally resorbed
Diethyl glycol dimethyl Mouse +/-
ether
Diethylhexyl phthalate Mouse +/-
Ethylene glycol Rat NC Maternal and develop-
mental toxicity at
lowest dose (probably
in category +/+)
Ethylene glycol Mouse +/-
Ethylene glycol diethyl Mouse +/-
ether
a-Methyldopa Mouse -/+ Decreased weight gain by
mothers at 250 mg/kg
in absence ofdevelop-
mental toxicity
NC, not classifiable.
aOutcome code is reported as positive or negative developmental toxici-
ty/positive or negative maternal toxicity.
Table 6. Comparative maternal toxicity: maternal LOAEL.
Chemical Dose units Mouse Rat Rabbit
Acetone ppm in air 6600 11000 -
Acrylamide mg/kg 15 7.5 -
Arsine ppm in air 2.5 2.5 -
Bisphenol A mg/kg >500 >160 -
Boric acid mg/kg 1003 163 250
1,3-Butadiene ppm in air 200 1000 -
Butyl benzyl phthalate mg/kg 2330 1100 -
Carbon disulfide mg/kg - 200 75
Chlorpromazine HCI mg/kg 5 >5 -
Codeinea mg/kg 150 - -
Diethylene glycol diethyl mg/kg 1500 - 400
ether
Diethylene glycoldimethyl mg/kg 250 - 100
ether
Diethylhexyl phthalate mg/kg 191 666 -
Diphenhydramine mg/kg > 80 50 -
Ethylene chlorohydrin mg/kg 120 - 18
Ethylene glycol mg/kg 1500 21250 2000
Ethylene glycol diethyl mg/kg 1000 - 100
ether
Gallium arsenide mg/mi3 >10 37 -
Gentian violet mg/kg - 5 >0.5
n-Hexane ppm in air >5000 1000 -
Hydrochlorothiazide mg/kg >3000 1000 -
L,5-Hydroxytryptophan mg/kg <50 300 -
Isoprene ppm in air 7000 >7000 -
a-Methyidopa mg/kg 250 100 -
Nitrofurazone mg/kg 82 - 20
Oxytetracycline mg/kg >1325 >1200 -
Phenol mg/kg 280 >120
Scopolamine HBr mg/kg 450 100 -
Sulfamethazine mg/kg - 865 1200
Tetrahydrofuran ppm in air 1800 5000 -
Theophylline mg/kg 372 259 -
Triethylene glycol mg/kg >1000 - 175
dimethyl ether
LOAEL, lowest-observed adverse effect level.
aMaternal LOAEL in hamster was 150 mg/kg.
in the profile of developmental toxicity observed. Thus, the
results of these studies have been summarized according to
species regarding the developmental toxicity observed at or
abovethe LOAEL(Table9). Theanalysisofthis informationby
species is summarized inTable 10. Asexpected formiceandrats,
theobservationthatdeterminedtheLOAELthegreatestpercen-
tageoftimewasadecreaseinfetalbodyweight. Thenumberof
timestheLOAELwasdeterminedby anincreaseintheincidence
of variations in all three species is noteworthy because the
LOAELwasdeterminedbyanincreaseintheincidenceofvaria-
tions in one study in each species (3-10% of the studies with
somedevelopmental toxicity). Theimportanceoftheprofileof
developmentaltoxicityobservedabovetheLOAELversustheef-
fectobserved atthe LOAEL (Table9) probably deserves more
consideration thanhas beencustomary. Forcertainchemicals,
the only effect observed at the LOAEL was, for example, a
significantdecreaseinfetalbodyweight. Athigherdoselevels,
otherendpointswere "recruited" aspartoftheprofileoftoxicity.
With otherchemicals, theeffectobserved atthe low dose level
occurred to a progressively greater extent at higher doses, but
there was no recruitment ofother end points. Intuitively, this
wouldseemtosaysomethingaboutthepotential fordevelopmen-
taltoxicity inother species. Furtheranalysis ofthis ideawould
seem to be warranted.
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Table 7. Developmental toxicity outcomeasafunctionofmaternalLOAEL.
LOAEL, Outcome
-_ . Species Chemical
LOAEL <50mg/kg
Rat Acrylamide
Chlorpromazine
Diphenhydramine
Gentian violet
Isoproterenol
Mouse Acrylamide
Chlorpromazine
1,2,3,4,7,8-Hexachlorodibenzofuran
L,5-Hydroxytryptophan
1,2,3,7,8-Pentachlorodibenzofuran
2,3,4,7,8-Pentachlorodibenzofuran
Perfluorodecanoic acid
Rabbit Ethylene chlorhydrin
Ethylene oxide
Gentian violet
Nitrofurazone
LOAEL in range of50-500 mg/kg
Rat Bendectin
Bisphenol A
Boric acid
Carbon disulfide
Ethylene glycol monobutyl ether
L,5-Hydroxytryptophan
a-Methyldopa
Phenol
Scopolamine
Theophylline
Mouse Bisphenol A
Codeine
Diethylene glycol dimethyl ether
Diethylhexyl phthalate
Diphenhydramine
Ethylene chlorohydrin
Methacrylamide
a-Methyldopa
Phenol
Scopolamine
Theophylline
Rabbit Boric acid
Carbon disulfide
Diethylene glycol diethyl ether
Diethylene glycol dimethyl ether
Ethyleneglycol diethyl ether
Triethylene glycol dimethyl ether
Hamster Codeine
LOAEL in rangeof500-1000 mg/kg
Rat Diethylhexyl phthalate
Sulfamethazine
LOAEL >1000mg/kg
Rat Butyl benzyl phthalate
Diethyl phthalate
Dimethyl phthalate
Dipropylene glycol
Hydrochlorothiazide
Oxytetracycline
Mouse Butyl benzyl phthalate
2,3-Dideoxycitidine
Diethylene glycol
Diethylene glycol diethyl ether
Ethylene glycol
Ethylene glycol diethyl ether
Hydrochlorothiazide
Oxytetracycline
Triethylene glycol dimethyl ether
Rabbit Ethyleneglycol
Sulfamethazine
mg/kg categorya
7.5
<5
50
<20
15
5
<50
0.1
0.02
6.4
18
18
20
500
>160
163
200
100
300
100
>120
100
259
<500
iSOb
250
191
80
120
120
250
280
450
372
250
75
400
100
100
175
150b
666
865
1100
3214
3570
2000
1000
<1200
2330
2000
5000
1500
1500
1000
>3000
. 1325
>1000
2000
1200
-/+
NC
-/+
-/+
NC
-/+
-/+
+/-
-/+
+/-
+/-
+/-
-/+
NC
NC
+/+
+/+
-/+
+/-
+/+
-/+
+/+
+/+
+/-
+/+
+/-
-/+
+/+
+/-
+/-
-/+
+/-
+/+
-/+
+/+
+/+
+/+
+/+
+/-
-/+
+/+
+/-
+/+
+/-
+/+
+/-
+/+
+/+
-/+
-/+
-/+
NC
+/+
+/-
-/+
-/+
+/-
+/-
NC
-/+
+/-
-/+
-/+
Tible 8 Summary ofstudy outcome asafunction ofLOAEL
formaternal toxicity.
Maternal LOAEL, mg/kg/day
Study outcomea <50 50-500 500-1000 >1000 Total
+/_ 4 (25%)b 9 (32%) 1(50%) 4 (24%)
+/+ 1(6%) 13 (46%) 1(50%) 3 (18%)
-/+ 7 (44%) 6 (21%) 0 (0%) 8 (47%)
NC 4 (25%) 0 (0%) 0 (0%) 2 (12%)
Total 16 28 2 17 63
+/- 4 (22%)C 9 (50%) 1(6%) 4 (22%) 18
+/+ 1(6%) 13 (72%) 1 (6%) 3 (17%) 18
-/+ 7 (33%) 6 (29%) 0 (0%) 8 (38%) 21
NC 4(67%) 0(0%) 0 (0%) 2 (33%) 6
Total 63
Abbreviations: NC, notclassifiable; LOAEL, lowest-observedadverseeffect
level.
aOutcome is reportedaspositiveornegativedevelopmental toxicity/positive
ornegative maternal toxicity.
bNumberandpercentageofstudies percategory ofmaternaltoxicity (i.e., 4/16
= 25%).
cNumberandpercentage ofstudies percategory ofstudy outcome (i.e., 4/18
= 22%).
We have also questioned whether fetal body weight or fetal
body weightplus resorptions wouldpredicttheoutcomebased
onanalysisofallendpointsofdevelopmentaltoxicity studies. If
thisweretrue, theexpensiveinvestmentofresourcestoconduct
the analysis for malformations and variations would not be
necessaryinaninitialscreen, sinceconcordancebetweenspecies
islowandtheusefulnessofthedatawouldnotbecompromised.
The result ofthis analysis is summarized in Table 11. Unfor-
tunately, adecisiononthebasisofthecombinationofthechange
inbody weightorincidenceofresorptionsdidnotidentifyallof
the agents in which developmental toxicity was detected. This
rangedfrom75% oftheagentsin ratsto86% inmice. Asignifi-
cant percentage ofthe agents caused malformations and varia-
tions without any change in fetal body weight or resorptions.
The NTPdata set is notoptimum foransweringthequestion
ofhow wellonelaboratory animal speciespredictstheoutcome
for other animal species because studies were not necessarily
conducted intwoorthreespecies. Inmanycases, thechemicals
wereselectedbecauseonespecies/study wasalready reported in
theliterature, andweexpandedthedatabasetoincludeanaddi-
tional species. However, thebestdatawehaveforcomparingthe
species responses ispresented inTable3, wherethestudies that
wereconducted inmultiple species are summarized according
totheoutcomecategory. The mostrevealingobservation is the
numberofchemicalsthatwerefoundtobeselectivedevelopmen-
taltoxicantsinmorethanonespecies. This includesboricacid,
ethylene glycol diethyl ether, and ethylene glycol monobutyl
ether. Thenumberofchemicalsthatwereinthecategory where
therewasnodevelopmentaltoxicity inthepresenceofsignificant
maternal toxicity was greater, including acrylamide, arsine,
bisphenolA, diethyleneglycoldiethylether, anddiphenhydra-
mine. Definitiveconclusions aboutinterspeciespredictiveness
wouldrequirereviewofallavailabledataonalargernumberof
chemicals.
Status of in VitroTeratology Screens
Invitroterwologyassays havethepotential tobeofgreatutility
both in mechanistic and screening applications. However, the
Abbreviations: NC, notclassifiable; LOAEL, lowest-observedadverseeffect
level.
aOutcome code reported as positive or negative developmental toxicity/
positive ornegative maternal toxicity.
hTwo times daily.
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Table9. Manifestations ofdevelopmental toxicityatandabovetheLOAEL.
Developmental toxicity
Chemical At LOAEL Above LOAEL
Mice'
Boric acid
1,3-Butadiene
Chlorpromazine
Codiene
2,3-Dideoxycytidine
Diethylene glycol dimethyl ether
Diethylhexyl phthalate
Ethylene chlorohydrin
Ethylene glycol
Ethylene glycol diethyl ether
Gallium arsenide
1,2,3,4.7.8-Hexachlorodibenzofuran
L,5-Hydroxytryptophan
Isoprene
Methacrylamide
a-Methyidopa
Mono(2-ethylhexyl) phthalate
2.3.4,7,8-Pentachlorodibenzofuran
1,2,3,7,8-Pentachlorodibenzofuran
Perfluorodecanoic acid
Phenol
Scopolamine
Theophylline
Triethylene glycol dimethyl ether
Rats"
Bendectin
Boric acid
Butyl benzyl phthalate
Carbon disulfide
Chlorpromazine
Diethylhexyl phthalate
Ethylene glycol
n-Hexane
Isoproterenol
a-Methyidopa
Oxytetracycline
Scopolamine
Theophylline
Rabbitsc
Carbon disulfide
Diethylene glycol dimethyl ether
Ethylene glycol diethyl ether
Gentian violet
Triethylene glycol dimethyl ether
BW
BW
BW
BW
BW, mal
BW
mal, var
BW
BW
mal
BW, var
BW, mal
var
BW
BW
BW,death, mal,
var
death, mal
mal
mal
BW
BW
BW
BW, death
BW
BW
BW
mal, var
BW
BW
BW
mal, var
BW
BW
BW
BW
BW
BW
death
death, mal, var
mal
BW
var
BW, death, mal, var
BW, var
BW, death, mal
BW, death
BW, death, mal
BW, death, mal, var
BW, death, mal, var
BW
BW, death, mal, var
BW, death, mal, var
BW, death, var
BW, mal
BW, var
BW, var
BW, death
BW, death, mal, var
BW, death, mal
mal
mal
BW
BW
BW
BW, death
BW, mal
BW, death, mal
BW, death, mal
BW, death, mal, var
BW
BW, death
BW, death
BW, death, mal, var
BW
BW, death
BW
BW
death, mal
BW
death, mal
death, mal, var
death, mal, var
BW
mal, var
Abbreviations: LOAEL, lowest-observed adverse effect level; BW, body
weight; mal, malformations; var, variations.
3LOAEL washighest dose in 12 studies; nodevelopmental toxicity was seen
in 3 studies.
'LOAEL was highest dose in nine studies; nodevelopmentaltoxicity was seen
in seven studies.
'LOAEL was the highest dose in five studies; nodevelopmental toxicity was
seen in three studies.
Table 10. Determinant oflowest-observed adverse effect level.
Mice Rats Rabbits
Fetal body weight 49 (17/35)' 68 (17/25) 20 (2/10)
Resorptions 3 (1/35) 4 (1/25) 30(3/10)
Malformations 9 (3/35) 12 (3/25) 10(1/10)
Variations 3 (1/35) 4 (1/25) 10 (1/10)
Two or more end points 37 (13/35) 12 (3/25) 30 (3/10)
No effects observed 10 (4/39)h 22 (7/32) 23 (3/13)
'Percentage (number of studies/number of studies with developmental
toxicity).
'Percentage (numberofstudies with nodevelopmental toxicity/total number
ofstudies).
Table 11. Percentageofstudieswithdevelopmental toxicitydetectedonthe
basisoftwo setsofobservations.
Species
Observations Mice Rats Rabbits
Fetal body weight or 86 (30/35) 76 (19/25) 80 (8/10)
resorptions
Fetal body weight, resorp- 100 88 100
tions, orexternal
malformations
considerable effort using in vitro assays to better understand
mechanismsofactionofteratogensanddevelopmentaltoxicants
has had limited success because ofthe complexity ofembryo-
genesisandthemultiplicityofmechanismsofabnormaldevelop-
ment. Whatweknowaboutmechanismshaslargelybeengained
through suchstudies, butwestill knowvery littleaboutmecha-
nismsofabnormaldevelopment. Theuseofin vitrosystemsfor
screening large numbers ofuntested chemicals has not been a
panacea either. Very few screens havebeen validated and none
isbeingusedforwide-scale screeningofchemicalsfromdiverse
classes ofchemical structure or function. The only assays that
haveundergonerigorousevaluationinindependentlaboratories
are two examined by the NTP: the human embryonic palatal
mesenchymalcell growthinhibition assayandthemouseovarian
tumor cell attachment inhibition assay (11).
A workshop was sponsored by the NTP in 1989to reevaluate
theneedforanduseofin vitroteratologyassays, toexaminethe
validationprocessforin vitrotests, andtodiscussprogress inthe
validationofin vitro teratology screens. A summaryofthiscon-
ference has been published (12). The participants ofthis con-
ferenceenthusiastically supported furtherdevelopmentofshort-
term in vivo and in vitro systems both as prescreens for devel-
opmental toxicity and as experimental systems to explore
mechanismsofactionoftoxicants. Several industriallaboratories
havedeveloped in vitro screens forassayingparticularfamilies
ofchemicalswhere acombination ofin vivoand in vitrodevel-
opmentaltoxicity information isalready established. Thein vitro
screens areusedtocharacterizeothermembers inthefamily of
chemicals. There was general agreement, though, that too few
in vitro teratology prescreens have been evaluated under
multiple-laboratory conditions withcommon, agreed-upon test
agents to draw firm conclusions regarding the merit and
reproducibility of in vitro teratology prescreens. There was
strong endorsement oftheneed todevelop anupdated reference
list(goldstandard) ofchemicalsofknowndevelopmentaltoxicity
potential to enhance further development and validation of
prescreens. Thislatterrecommendationhasbeenpursuedbythe
NTPthroughtheformationofacommitteetodevelopsuchanew
reference list.
Summary Observations on the
Status of Developmental Toxicology
and Role of the NTP
Inthecontextofthe maturation ofthefieldofdevelopmental
toxicology overthepast20yearsandtheroleoftheNTPoverthe
past 11 years, severalpoints warrantfurtherdiscussion. Firstare
commentsonsomespecificchemicals, thenonanimalmodels,
and observations about specific contributions by the NTP.
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The toxicity caused by certain chemicals within the NTP
database is noteworthy because ofthe severity and the nature of
the response. For example, administration ofboric acid to mice
caused a 33% decrease in fetal body weight at a concentration in
feed (0.4%) that provided adose ofabout 1 g/kg/day. At the oral
maximum tolerated dose to rabbits (250 mg/kg/day), there was
no effecton fetal body weight. In contrast to no response in the
rabbit and a modest response in the mouse, there was a 53 %
decrease in fetal body weight in litters ofrats given boric acid in
feed at a concentration (0.8%) that provided a dose of 539
mg/kg/day. Thus, forthe end point ofdecreased fetal body weight
after administration orally during major organogenesis, there
was a significant species difference in response, with the pres-
ence ofan unusually severe response in the rat. (Boric acid may
represent a useful model chemical for studying growth re-
tardation.)
Another interesting response is the severe and divergent effects
of2',3 '-dideoxycytidine and 2,3,4,7,8-pentachlorodibenzofuran
(PCDF) in C57BL/6N mice. Although both are true teratogens
inthe sense ofcausing anincrease in structural malformations,
the profile was widely different. Cleft palate and dilated renal
pelvis were observed in nearly 100% oflitters and pups at dose
levels ofPCDF that caused little or no maternal toxicity (these
pupswereexamined onlyforcleftpalate anddilatedrenal pelvis,
plus resorptions and weight, becauseTCDD and the structurally
related tetrachlorodibenzofuran caused no other structural altera-
tions). In contrast to this very selective toxicity caused by these
dioxins and furans, 2 ',3 '-dideoxycitidine caused asignificant in-
crease (againabout 100% oflitters and fetuses) in awide variety
ofmalformations representing many organ systems, butdid not
cause asignificant increase in cleftpalate or renal lesions. There
wasonly amarginally significant increased trend forcleftpalate.
The importance of this difference in profile of malformations
caused by these two potent mouse teratogens for risk assessment
considerations is unclear and awaits more mechanistic research.
Another subsetofchemicalsthat is unique includes those that
causeddevelopmental toxicity not only in multiple species, but
also in multiple end points in those species. This includes boric
acid, diethylene glycol dimethyl ether, diethylhexyl phthalate,
andethylene glycol diethyl ether. Notall ofthe chemicals tested
by the NTP were evaluated in multiple species, and this review
does not take into account other published literature, but from
ourdatabase, these four chemicals caused adevelopmental tox-
icity responsethat raises more concern aboutpotential riskthan
many other chemicals.
The potential correlation between theability of achemical to
cause nonreproductive toxicity and to cause developmental tox-
icity was important to the NTP as it relates to our mission to
characterize the toxicity ofchemicals. Ifthere was acorrelation,
it would have been a useful guide to help us discover new,
previously unidentified developmental toxicants of particular
public health concern. In the absence of such a predictive
criterion, other factors will be used to select chemicals for
testing.
In a search to reduce the cost oftesting by eliminating non-
productive portions ofthe standard developmental toxicity pro-
tocol, weconfirmed that nosingleendpointoftoxicity predicts
a response atall other endpoints. Thus, a protocol that includes
measures of body weight, resorptions, and the incidence of
malformations and variations appears to be necessary forbroad-
scale screening ofchemicals.
Identification and quantification ofmaternal toxicity in these
NTP studies was more thorough and consistent over the years
than for any other publicly available collection ofdevelopmen-
taltoxicity data. Despite this background ofdata andexperience,
subtle measures ofmaternal toxicity continue to challenge inter-
pretation onaconsistent basis. Forexample, transient and rever-
sible pharmacologic effects may or may not be considered evi-
dence of toxicity. Changes in organ weight consistent with
physiological adaptation may be statistically significant but not
oftoxicological importance. These and other findings that tend
tobechemical specific andofuncertain toxicological importance
continue to be interpreted on a chemical-by-chemical basis.
Lastly, thedataand experience ofthe NTPhaveplayed a focal
role in decisions that have affected the whole field of devel-
opmental toxicology. NTP test results continue to support
regulatory decisions and the data help provide bases for
regulatory test guidelines and risk assessment guidelines.
Workshops sponsored by the NTP have addressed critical issues
and have provided a neutral and scientific arena to resolve
divergences inthe field and to foster discussions ofdirections and
priorities forthe field. Recent workshops includeoneon valida-
tionofinvitroteratology screens (September, 1989), another on
the interpretation ofSegmentII test results (June, 1991), and most
recently oneon lactation as atarget forchemical-induced toxicity
and as ameansofneonatal exposure totoxicants (March, 1992).
Consistent with its charter, the NTPhas made significant con-
tributions inthe area ofmethods development and validation in
the areaofdevelopmental toxicity screens. Through the National
Institute for Occupational Safety and Health component ofthe
NTP, the Chernoff-Kavlock test was rigorously evaluated, in-
cluding a workshop to pull together data and experience with the
test. Drosophila is being evaluated as apotential screen. Two in
vitro systems were the subject offormal validation studies by the
NTP, theonly developmental toxicity screens to receive such an
intensive evaluation. To further guide validation efforts in the
future, the NTP has organized a comittee ofexperts to develop
a new listofreference chemicals to provide focus to this impor-
tant process.
The NTPdatabase has served as a valuable resource in recent
efforts todevelop better methods to analyze developmental tox-
icity data. Because ofthecompleteness ofthedata, theconsisten-
cy of the protocol and quality control over the years, and the
public availability of the data, the database has been used by
academic and regulatory scientists to evaluate the use of the
benchmark dose approach and otherways to model developmen-
tal toxicity data.
The NTPhas been able to conduct studies that are important
to the field but would never be conducted by the private sector
and would notbe supported through grant mechanisms. For ex-
ample, the NTPconducted retrospective and prospective studies
todetermine ifthere wasany toxic effect from the useofcorn oil
as a vehicle.
Insummary, NTPdataand scientists have servedan important
role inthecontinued evolution ofthe field ofdevelopmental tox-
icology. Future plans ofthis national program assure this as a
continuing role.
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Future Directions in Developmental
Toxicology
Although considerable protection ofpublic healthhasbeen af-
forded through the work that has been done during the past 25
years, future progress isdependent onseveralmain areasoffur-
ther research and model development.
Information Related to Animal Models in
Current Use
As mentioned earlier, developmental toxicity studies are cur-
rently interpreted on an empirical basis because of our lack of
understanding ofthe processes involved innormaldevelopment
and a lack ofunderstanding of mechanisms oftoxicity. To go
beyond an empirical observation, we mustbetterunderstand the
biological basis ofthe physiological processes involved in nor-
mal embryonic, fetal, and postnatal development. Until we
understand normal development, we will not be able to under-
stand mechanisms ofabnormal development to any great extent.
Modern tools ofdevelopmental biology and molecularbiology
provide a newopportunity tobetterunderstand normaldevelop-
ment. The field must incorporate these techniques to take a
significant step forward beyond the empirical interpretation of
our studies.
Another areaofworkthatwouldenhance ourability to usethe
information from animal studies inpredicting potential hazards
to humans would be a more thorough evaluation ofthe known
human positive agents using standardanimal models. Many of
the agents that we consider to be developmental toxicants or
teratogens in humans have not been thoroughly studied using
standard developmental toxicity protocols. Onceconfirmed as
ahumantoxicant, studiesby mostinvestigators arelimited tothe
specific areaofresearch interestofthatinvestigator. As aresult,
much ofthe work involvesfollow-up studies on aspecific malfor-
mation and attempts to mimic theeffects observedinhumans in
an animal model. Thus, we have limited data to evaluate the
predictiveness ofthe typeofresponsein adevelopmental toxicity
study forthatobserved inhumans. Thiscouldbeaccomplished
by conducting standard developmental toxicity studies on those
agents known to causetoxicity inhumans. Suchdata would per-
mitthe firstsubstantiveevaluationofthequestionsofinterspecies
concordance oftoxic effects and relative sensitivity ofspecies
based on potency anddiversity oftoxic response. Forexample,
the NTP studies confirm the high frequency ofgrowth retarda-
tion in mice and rats as theeffect whichdeterminedthe LOAEL.
Is this a function of the short time between the last dose of
chemical and the time ofCaesarean section and is, therefore,
unique to rodents, or is itpredictive oftoxicity inhumans?
Further work must alsobedone to evaluate the importanceof
confounders (adult toxicity, altered food or waterconsumption,
etc.) on the interpretation ofdevelopmental toxicity studies. The
importance of these confounders in,the interpretation ofdata,
along with the importance of variants, remains a source of
disagreement in the interpretation oftest data.
Morequantitative methods foranalyzing testdata areclearly
required tobetterpredictthe extent andtypeofriskforhumans.
However, intheabsence ofmechanistic understanding, itwill be
difficult to make major steps forward in these quantitative
methodsofpredicting risks. Aninterim step isbeingtaken to at
leastuse moreofthedatabase upon which to make safety deci-
sions, basedonthederivationofbenchmarkdoses(13). Thisap-
proach still involves the use ofuncertainty factorsand does not
predict riskper se, but isdefinitely a step in the right direction
to incorporate the slope ofthe dose response curve rather than
determine safety simply from a NOAEL.
Clearly, thefield also needs to identify markersofeffect and
susceptibility. Tomovethefieldofepidemiology forwardintothe
realm ofmolecular epidemiology requires the development of
sensitive markers to better define exposure, to improve our
predictionofpregnancyoutcome, andtohelpidentify sensitive
subpopulations ofpeople.
Chemical-specific Information
We need to continue todefine mechanisms and modes ofac-
tion, thesiteofaction, and identification ofproximatetoxicants
to better understand chemical-induced developmental toxicity.
Major stepsforward inextrapolationbetween specieswill only
come with increased knowledge oftarget-site dosimetry. Our
definitionofexposureascurrentlyusedformoststudies(mg/kg
givenorallyorappliedtotheskin, ppmormg/m3 ininhaledair)
are poor surrogates for dose. Much of the confusion in the
literature about extrapolation between species is probably at-
tributable to our poor definition ofdosimetry and inadequate
scaling efforts. Therelativeimportanceofpeakbloodlevel ver-
sus areaunder-the-curveconsiderationsaredefinitely important
topursue. Ourabilitytopredictonthebasisofstructureactivi-
tyandreactivity isverylimitedinthefieldofdevelopmental tox-
icology. Predictions within chemical families, such as glycol
ethers, are relatively accuratebutpredictions across families of
chemicals are poorly founded.
New TestMethods
It is clearthatbetter screens wouldbe helpful inprioritizing
agentsthatshouldbetestedinmoredefinitiveprotocols as con-
firmed at the NTP workshop on in vitro methods. This would
consistofinvitromethods, testsystemsusingalternatespecies,
aswellasimprovedshort-termmammaliantests. Weneedanimal
models that are specific for discrete parts ofthe complex bio-
logical processes that account for normal development. These
models should be selected to incorporate specific points of
vulnerability indevelopment, pointsthatwouldpredicttheout-
comeofthe morecomplexdevelopmental toxicity screens that
are a compositeofall ofthese parts ofdevelopment.
Exposure Parameters
Additionalworkneedstobeconductedtorefineourability to
measure internal doses at critical sites. Further work must be
done toidentify sensitivesubpopulations andotherfactors that
accountforobserveddifferences ininterindividual susceptibility.
Because riskassessmentinvolves scaling factors thatprobably
vary by age and end point, additional work to provide a better
basisforthesescalingfactors iswarranted. Also, riskassessment
will continue to require extrapolation between routes of ex-
posure, anareawheredataarefrequently very limitedtopermit
informed extrapolation across routes.
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